Testimonials & Benchmarks

These testimonials from our partners highlight how collaboration with our team enables delivery of exemplary clinical research.

68
No of Studies Conducted in Total (1995 - 2017)
42
No of Recent Studies (2013 - 2017)
344
No of Recent Patients Enrolled (2013 - 2017)
82%
Median Retention Rate (%)
16%
Median SF Rate (%)
Aztherapies

Aztherapies

1. 6. 2022

I have been very impressed with the quality of data generated by VestraClinics under the direction of Dr. Pazdera.

Alzheon

Alzheon

6. 5. 2022

The Vestra Clinic was the first active site in our biomarker study in Alzheimer’s patients, and enrolled our first subject into the trial.

Pharmatropix

Pharmatropix

3. 5. 2022

The team successfully screened 39 subjects and 26 were randomized. Communications were timely and efficient; timelines were met and audits found no critical or major findings.

Olain farm

Olain farm

3. 3. 2022

This is to confirm the participation of Vestra Clinics, s.r.o., Rychnov nad Kneznou, Czech Republic, in clinical study sponsored by JSC Olainfarm in patients with lumbosacral radiculopathy.

Bayer s.r.o.

Bayer s.r.o.

7. 10. 2021

This memo is to confirm the participation of Vestra Clinics in the PUCCINI study that assess the efficacy and safety of BAY 1817080 in patients with diabetic neuropatic pain. The Principle Investigator was Dr. Ladislav Pazdera.

Teva

Teva

19. 6. 2019

This memo is to confirm the participation of Vestra Clinics in the FOCUS study of Teva Pharmaceuticals Evaluating the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients with Inadequate Response to Prior Preventive Treatments. Principal Investigator was Dr. Ladislav Pazdera.

Axovant

Axovant

6. 3. 2018

This memo will confirm the participation of Vestra Clinics sro in Axovant's MINDSET study that compared RVT-101 35 mg to placebo in patients with mild to moderate Alzheimer's disease. The Principal Investigator was Dr. Ladislav Pazdera.